Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy

Keyphrases

• Bone Marrow Graft 8%
• CD3+ Cells 8%
• Chemotherapy 8%
• Chimerism 41%
• Donor chimerism 8%
• Donor Lymphocyte Infusion 100%
• Donor Lymphocytes 8%
• Extramedullary Relapse 8%
• First Dose 8%
• G-CSF Mobilized Peripheral Blood 8%
• Graft-versus-host Disease (GvHD) 41%
• Haploidentical Hematopoietic Stem Cell Transplantation 100%
• Hematologic 8%
• High Risk 8%
• Peripheral Blood 16%
• Peripheral Blood Stem Cell Graft 100%
• Persistent Disease 8%
• Post-transplantation Cyclophosphamide (PTCy) 100%
• Relapse Risk 8%
• Relapse-free Survival 8%
• Salvage Therapy 8%

Medicine and Dentistry

• Acute Graft Versus Host Disease 25%
• Bone Marrow Transplantation 8%
• CD3 Antigen 8%
• Cell Transplantation 100%
• Chronic Graft Versus Host Disease 8%
• Cyclophosphamide 100%
• Diseases 8%
• Donor Lymphocyte Infusion 100%
• Granulocyte Colony Stimulating Factor 8%
• Hematopoietic Cell 100%
• Identified Patient 8%
• Lymphocyte 8%
• Patient History of Chemotherapy 8%
• Peripheral Blood Stem Cell 100%
• Recurrence Free Survival 8%
• Salvage Therapy 8%

Immunology and Microbiology

• Acute Graft Versus Host Disease 23%
• CD3 Antigen 7%
• Cell Transplantation 100%
• Chronic Graft Versus Host Disease 7%
• Cyclophosphamide 100%
• Granulocyte Colony-Stimulating Factor 7%
• Hematopoietic Cell 100%
• Lymphocyte 100%
• Peripheral Blood Stem Cell 100%
• Recurrence Free Survival 7%